Intellipharmaceutics International (IPCI) Receives Daily Coverage Optimism Rating of 0.03

Headlines about Intellipharmaceutics International (NASDAQ:IPCI) (TSE:I) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Intellipharmaceutics International earned a news impact score of 0.03 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.2750209909372 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several equities research analysts have recently commented on the company. Zacks Investment Research downgraded Intellipharmaceutics International from a “hold” rating to a “sell” rating in a report on Friday, July 14th. Maxim Group set a $6.00 price objective on Intellipharmaceutics International and gave the company a “buy” rating in a report on Friday, July 21st. ValuEngine downgraded Intellipharmaceutics International from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, Mackie upgraded Intellipharmaceutics International to a “hold” rating and boosted their price objective for the company from $1.00 to $3.10 in a report on Tuesday, September 26th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $3.78.

Intellipharmaceutics International (NASDAQ IPCI) traded down 0.93% during midday trading on Friday, hitting $1.06. The stock had a trading volume of 565,982 shares. Intellipharmaceutics International has a 12 month low of $0.81 and a 12 month high of $3.35. The company’s market cap is $32.41 million. The firm’s 50-day moving average price is $1.01 and its 200 day moving average price is $1.74.

ILLEGAL ACTIVITY WARNING: “Intellipharmaceutics International (IPCI) Receives Daily Coverage Optimism Rating of 0.03” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/10/14/intellipharmaceutics-international-ipci-receives-daily-coverage-optimism-rating-of-0-03.html.

Intellipharmaceutics International Company Profile

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Insider Buying and Selling by Quarter for Intellipharmaceutics International (NASDAQ:IPCI)

Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply